Zoetis Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Fri, August 7, 2026 at 12:51 AM GMT+3 3 min read

ZTS -5.97%

Zoetis Inc. Q2 2026 Earnings Call Summary - Moby

Strategic Performance Drivers and Market Dynamics

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Performance fell short of expectations due to a multiyear trend of declining veterinary clinic visits and pet owners becoming more selective in spending as price increases outpaced inflation.
Management observed a shift in the nature of competition where new entrants are using high levels of discounting, rebates, and cross-portfolio bundling to capture existing patients rather than expanding the market.
U.S. revenue declined 7%, while the U.S. Companion Animal sub-segment declined 11%., driven by significant pressure in Dermatology and parasiticides where competitive intensity and affordability concerns were most pronounced.
Livestock delivered strong 11% growth, providing a critical hedge against Companion Animal weakness, though some drivers like New World screwworm demand are considered transitory.
The company is responding with 'gross-to-net' investments—targeted promotions and rebates—to protect volume and share without permanently altering long-term list prices.
Organizational changes, including the appointment of a new CFO/COO and a new President of U.S. Commercial Operations, are designed to accelerate decision-making and execution agility.
Diagnostics remains a strategic catalyst, growing 12% as clinic revenue shifts toward urgent care and the company expands into veterinary imaging interpretation via the VitalRADS acquisition.

Revised Outlook and Strategic Assumptions

Full-year organic operational revenue guidance was revised to a decline of 3% to 1%, reflecting the assumption that current market pressures will persist or potentially accelerate.
The low end of the guidance range accounts for a scenario where July's market weakness continues through the second half with greater share losses in key categories.
Management expects to maintain aggressive gross-to-net investments until market share and volume stabilize, prioritizing near-term defense over immediate margin expansion.
Innovation remains the primary long-term growth driver, with the anticipated U.S. approval of long-acting Cytopoint and the commercial validation of the Vetscan OmniMax platform expected by year-end.
Cost discipline initiatives, including reduced discretionary spend and compensation-related expenses, are expected to continue providing a partial offset to revenue headwinds.

Structural Changes and Risk Factors

Jay Saccaro will join as EVP, CFO, and COO on August 17, a new role combining finance with global manufacturing and supply to improve supply chain connectivity.
Foreign exchange headwinds are estimated to impact the top line by approximately $60 million to $65 million and the bottom line by about $30 million for the full year.
Generic competition for Cerenia and Convenia in the U.S. necessitated pricing adjustments to support dose recapture, albeit at lower realized price points.
The company increased share buyback activity to over $550 million in the quarter, citing current valuation as an attractive use of capital despite operational headwinds.

Q&A Session Highlights

Strategic rationale for gross-to-net pricing versus list price changes

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management clarified they are avoiding list price cuts because they are permanent structural changes that are difficult to reverse once the market recovers.
Gross-to-net investments (rebates and promos) allow for targeted, time-bound defense of volume and share at the point of sale or for new patient starts.

Duration and triggers for pulling back on promotional activity

Promotional intensity is currently driven by a combination of new competitor launches and macro affordability challenges.
The company will consider reducing these investments once quarter-over-quarter market share trends show clear stabilization.

Product differentiation in a 'good enough' value-conscious market

Management acknowledged that while their products (Trio, Apoquel) have superior safety and efficacy, pet owners may trial cheaper alternatives due to budget constraints.
They noted early signs in Europe of pet owners switching back to Zoetis products after experiencing competitors, reinforcing their belief in long-term differentiation.

Sustainability of Livestock growth and transitory drivers

Second-half Livestock growth is expected to moderate to the mid-single-digit range as Q2 benefited from transitory supply timing and specific disease outbreaks.
Underlying fundamentals remain solid, supported by favorable producer economics and global protein demand.